Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases

<p>Topographic immune cell deconvolution primary colorectal cancer and CRLM. <b>A,</b> Images (from <a href="#fig4" target="_blank">Fig. 4A</a>) of primary colorectal cancer (bottom) and CRLM (top) with 48 ROIs superimposed. Abundance estimates as de...

Saved in:

書目詳細資料
主要作者:	Colin S. Wood (15293247) (author)
其他作者:	Kathryn A.F. Pennel (15293250) (author), Holly Leslie (15293253) (author), Assya Legrini (15293256) (author), Andrew J. Cameron (15046037) (author), Lydia Melissourgou-Syka (15293259) (author), Jean A. Quinn (15293262) (author), Hester C. van Wyk (15293265) (author), Jennifer Hay (15293268) (author), Antonia K. Roseweir (15293271) (author), Colin Nixon (14949516) (author), Campbell S.D. Roxburgh (15293274) (author), Donald C. McMillan (15293277) (author), Andrew V. Biankin (14937726) (author), Owen J. Sansom (14949234) (author), Paul G. Horgan (15293280) (author), Joanne Edwards (14939606) (author), Colin W. Steele (15293283) (author), Nigel B. Jamieson (15046064) (author)
出版:	2025
主題:	Cancer Tumor Biology Cancer Detection and Diagnosis Methods and Technology Biomarkers Diagnostic biomarkers Gastrointestinal Cancers Colorectal cancer Gene Technologies High-throughput sequencing Progression, Invasion & Metastasis
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
由: Colin S. Wood (15293247)
出版: (2025)

Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i><sup>+</sup> Macrophages and Fibroblasts
由: Anuja Sathe (15028097)
出版: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
由: Iris van 't Erve (15054503)
出版: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
由: Shuwei Li (16437116)
出版: (2025)

Supplementary table S2 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
由: Leon P. Loevenich (14963948)
出版: (2025)

Supplementary table S3 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
由: Leon P. Loevenich (14963948)
出版: (2025)

Supplementary table S4 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
由: Leon P. Loevenich (14963948)
出版: (2025)

Supplementary video file from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
由: Leon P. Loevenich (14963948)
出版: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
由: Katleen Janssens (15053356)
出版: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Figure S3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Supplementary Tables 1-3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
由: Subhamoy Chakraborty (16648124)
出版: (2025)

Supplementary Table S1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S7 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S8 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
由: Nan Deng (17314330)
出版: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Figures 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors
由: Luana Guimaraes Sousa (16534377)
出版: (2025)

Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
由: Priyanka Gopal (15050862)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3c48p9klsfa2hb3da5ds29a6be